Thursday, June 8, 2023
Clinical Advances in
Read Overview
Supported by an independent educational grant from
Incyte Corporation
Steering Committee Chair
Cell Biology and Biotherapy Unit
INT-Fondazione Pascale
Naples, Italy
Steering Committee Member
Oncologie Digestive
Département de Médecine Oncologique
Gustave Roussy
Villejuif, France
Steering Committee Member
Consultant in Medical Oncology
Fundacion Jimenez Diaz University Hospital,
Madrid, Spain
Steering Committee Member
Professor of Medicine
The University of Navarra School of Medicine
Pamplona, Spain
Steering Committee Member
Professor of Gastrointestinal Oncology
Hannover Medical School
Hannover, Germany
Steering Committee Member
Consultant in Gastroenterology & Hepatology
University Hospital Zurich and Lead Hepatology Basic Research Group
Zurich, Switzerland
Steering Committee Chair
Has disclosed the following relevant financial relationships:
Served as a speaker or a member of a speakers bureau for: AstraZeneca; Biocartis; Eli Lilly; Incyte; Merck; Merck Sharp & Dohme; Qiagen; Roche; Thermofisher
Received grants for clinical research from: AstraZeneca; Biocartis; Illumina; Qiagen; Roche; Thermofisher
Steering Committee Member
Has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Incyte, Merck Serono, Merck Sharp Dohme, Pierre Fabre Oncologie, Roche, Sanofi, Servier, Viatris
Other: Travel expenses for attending meetings: Amgen, Bayer, Bristol Myers Squibb, Merck Serono, Merck Sharp Dohme, Pierre Fabre Oncologie, Roche, Sanofi, Servier
Steering Committee Member
Has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Albireo Pharma; AstraZeneca; Boehringer Ingelheim; Boston Scientific; Eisai; GENFIT; Ipsen; Nutricia; QED; Roche; Servier
Served as a speaker or a member of a speakers bureau for: AAA; AstraZeneca; EISAI; Incyte; Ipsen; Merck; Pfizer; QED; Servier
Received grants for clinical research from: Ipsen; Roche
Other: Travel and education support: AAA; Bayer; Delcath; Ipsen; Mylan; Novartis; Pfizer; SirtEx
Steering Committee Member
Has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Adaptimmune; AstraZeneca; Bayer; Bristol Myers Squibb; Boston Scientific; Eisai; Incyte; Ipsen; Roche; Sirtex; Terumo
Served as a speaker or a member of a speakers bureau for: AstraZeneca; Bayer; Bristol Myers Squibb; Incyte; Ipsen; Roche; Sirtex; Terumo
Received grants for clinical research from: Bristol Myers Squibb; Roche; Sirtex
Steering Committee Member
Has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca; Bayer; Bristol Myers Squibb; BTG; Daichi-Sankyo; Eisai; GlaxoSmithKline; Imaging Equipment, Ltd. (AAA); Incyte; Ipsen; Lilly; Merck; Merck Sharp Dohme; Novartis; Pierre Fabre; Roche; Sanofi; Servier; Sirtex; Terumo
Served as a speaker or a member of a speakers bureau for: AstraZeneca; Bayer; Bristol Myers Squibb; BTG; Daichi-Sankyo; Eisai; GlaxoSmithKline; Imaging Equipment Ltd. (AAA); Incyte; Ipsen; Lilly; Merck; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche; Sanofi; Servier; Sirtex; Terumo
Received grants for clinical research from: Servier
Steering Committee Member
Joachim Mertens, MD, FEBGH, has no relevant financial relationships.
